TY - JOUR
T1 - Pharmacologic and pharmacokinetic profile of mibefradil, a T- and L- type calcium channel antagonist
AU - Abernethy, Darrell R.
PY - 1997/8/21
Y1 - 1997/8/21
N2 - Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. This article will review pertinent results from in vitro, animal, and clinical investigations to report the pharmacologic properties that distinguish mibefradil from all of the calcium channel antagonists in use today, all of which operate on the 'L-type' calcium channel. Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris.
AB - Mibefradil is a recently introduced calcium antagonist that, as a tetralol derivative, is chemically distinct from previous calcium antagonists. This article will review pertinent results from in vitro, animal, and clinical investigations to report the pharmacologic properties that distinguish mibefradil from all of the calcium channel antagonists in use today, all of which operate on the 'L-type' calcium channel. Mibefradil's pharmacokinetic profile indicates it can be used as a once-daily oral treatment for hypertension and chronic stable angina pectoris.
UR - http://www.scopus.com/inward/record.url?scp=0030818271&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030818271&partnerID=8YFLogxK
U2 - 10.1016/S0002-9149(97)00564-X
DO - 10.1016/S0002-9149(97)00564-X
M3 - Article
C2 - 9286848
AN - SCOPUS:0030818271
SN - 0002-9149
VL - 80
SP - 4C-11C
JO - American Journal of Cardiology
JF - American Journal of Cardiology
IS - 4 B
ER -